Drug Search Results
More Filters [+]

Tarenflurbil

Alternative Names: tarenflurbil, r-flurbiprofen, mpc-7869, TMP-001, TMP001, TMP 001
Latest Update: 2023-06-15
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: JNK Activator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral,Topical

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Myrexis
Company Location: NEW YORK NY 10020
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tarenflurbil

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Alzheimer Disease

Phase 2: Dermatitis, Atopic|Prostate Cancer|Multiple Sclerosis, Relapsing-Remitting|Skin Cancer|Melanoma

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2014-004483-38

P2

Completed

Multiple Sclerosis, Relapsing-Remitting

2018-04-20

TMP001_MS

P2

Completed

Multiple Sclerosis, Relapsing-Remitting

2018-04-01

FLIP0112

P1

Completed

Healthy Volunteers

2014-09-01

2011-002571-42

P2

Completed

Dermatitis, Atopic

2012-04-19

Recent News Events